ALEX: alectinib is the best first-line therapy available for ALK-positive NSCLC VJOncology 1:56 6 years ago 2 262 Далее Скачать
Should a Second Generation ALK Inhibitor be First Line Therapy for Patients with ALK-Positive NSCLC? GRACE - Global Resource for Advancing Cancer Education 4:14 9 years ago 68 Далее Скачать
Dr. Shaw on Alectinib as First-Line Therapy in Lung Cancer OncLive 2:26 7 years ago 1 692 Далее Скачать
Key findings of the ALEX study: Improved therapeutic options for ALK-positive NSCLC VJOncology 1:39 6 years ago 79 Далее Скачать
Updated Data from Phase 2 Study of Alectinib in ALK–Positive Non–Small–Cell Lung Cancer VJOncology 2:00 7 years ago 340 Далее Скачать
Alectinib eclipses crizotnib for ALK positive lung cancer ecancer 4:00 7 years ago 1 737 Далее Скачать
Updates in ALK+ lung cancer: GLASS, ALEX, ALTA-1L and CROWN VJOncology 5:44 3 years ago 198 Далее Скачать
J-Alex Trial: Should Alecensa Replace Xalkori as First-Line ALK Therapy? GRACE - Global Resource for Advancing Cancer Education 11:02 8 years ago 817 Далее Скачать
NAUTIKA1: safety and tolerability of neoadjuvant alectinib in ALK-positive NSCLC VJOncology 0:56 2 years ago 534 Далее Скачать
Management of frontline ALK+ NSCLC: brigatinib vs. alectinib VJOncology 3:04 4 years ago 1 243 Далее Скачать
Dr. Christina Baik on Alectinib in Patients With ALK-Lung Cancer Targeted Oncology 1:12 8 years ago 513 Далее Скачать
Dr. Gandhi Discusses the Role of Alectinib in ALK+ Lung Cancer OncLive 0:41 7 years ago 326 Далее Скачать
Comparing Alectinib Versus Crizotinib in ALK+ NSCLC Targeted Oncology 1:06 7 years ago 356 Далее Скачать
Dr. Velcheti on Potential of Alectinib in Frontline ALK-Positive NSCLC OncLive 1:42 8 years ago 223 Далее Скачать
